Volume 48, Issue 4 pp. 364-368
Full Access

The Passage of Flunitrazepam into Cerebrospinal Fluid in Man

Leena Aaltonne

Leena Aaltonne

Department of Pharmacology, Turku University

Search for more papers by this author
Jussi Kanto

Jussi Kanto

The Departments of Anaesthesiology

Search for more papers by this author
Esko Iisalo

Esko Iisalo

Department of Pharmacology, Turku University

Search for more papers by this author
Kari Koski

Kari Koski

Neurology, Turku University Central Hospital, Turku, Finland

Search for more papers by this author
Matti Salo

Matti Salo

The Departments of Anaesthesiology

Search for more papers by this author
Taisto Siirtola

Taisto Siirtola

Neurology, Turku University Central Hospital, Turku, Finland

Search for more papers by this author
First published: April 1981
Citations: 8

Abstract

Abstract: The passage of flunitrazepam into cerebrospinal fluid (CSF) was studied in 23 surgical patients (group 1), after a single 0.02 mg/kg intravenous injection, in 9 otherwise healthy patients undergoing neurological examination (group 2), after a single 2 mg oral dose, and in 9 chronically-ill neurological patients (group 3), after 2 to 4 successive 2 mg oral doses. Flunitrazepam in plasma and the CSF was determined by gas chromatography and its plasma protein binding by equilibrium dialysis. Uptake of flunitrazepam into human CSF was found to be very fast: even 5 min. after intravenous injection the drug level in the CSF was 2.8 % of the corresponding plasma concentration. CSF levels increased up to 77 min. after intravenous injection. In group 2 the mean percentage level in the CSF was 23.5±13.0 (S.D.) and in group 3 it was 16.7±3.1. In group 1,22.9±8.0% of flunitrazepam was not bound to plasma protein, in group 2,12.1±8.3% and, in group 3,30.3±14.1 %. Groups 1 and 2 (P<0.01) and 2 and 3 (P<0.01) differ significantly from each other. In groups 2 and 3 there was no significant correlation between the percentage not bound to protein and CSF levels of flunitrazepam. The uptake of flunitrazepam by CSF provides an explanation for its rapid drug effects. Its binding to plasma protein is affected by disease and, possibly, by other drugs.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.